Великолепный мозг в любом возрасте

Kessler, R. С., P. A. Berglund, O. Dernier, et al. 2005. Lifetime prevalence and ageof-onset distributions of DSM- IV disorders in the National Comorbidity Survey Replication (NCS- R). Archives of General Psychiatry 62(6): 593–602.

ГАМК

Abdou, А. М., S. Higashiguchi, К. Horie, et al. 2006. Relaxation and immunity enhancement effects of gamma- aminobutyric acid (GABA) administration in humans. Biofactors 26(3): 201–208.

Cocito, L., A. Bianchetti, L. Bossi, et al. 1994. GABA 30 and phosphati-dylserine in human photosensitivity: A pilot study. Epilepsy Research 17: 49–53.

Green, M. L., R. G. Green, and W. Santoro. 1988. Daily relaxation modifies serum and salivary immunoglobulins and psychophysi-ologic symptom severity. Biofeedback &. Self Regulation 13: 187–199.

Loeb, С., E. Benassi, G. P. Bo, et al. 1987. Preliminary evaluation of the effect of GABA and phosphatidylserine in epileptic patients. Epilepsy Research 1: 209–212.

Гипербарическая оксигенация

Hopkins, R. О., L. К. Weaver, К. J. Valentine, et al. 2007. Apolipoprotein E genotype and response of carbon monoxide poisoning to hyperbaric oxygen treatment. American Journal of Respiratory and Critical Care Medicine 176(10): 1001–1006.

Lo, C. P., S. Y. Chen, M. C. Chou. 2007. Diffusion- tensor MR imaging for evaluation of the efficacy of hyperbaric oxygen therapy in patients with delayed neuropsychiatric syndrome caused by carbon monoxide inhalation. European Journal of Neurology 14(7): 777–782.

Инозитол

Barak, Y., J. Levine, A. Glasman, et al. 1996. Inositol treatment of Alzheimer’s disease: a double-blind, cross- over placebo controlled trial. Progress in europsychopharmacology and Biological Psychiatry 20(4): 729–735.

Carey, Р. D., J. Warwick, В. Н. Harvey, et al. 2004. Single photon emission computed tomography (SPECT) in obsessive- compulsive disorder before and after treatment with inositol. Metabolic Brain Disease 19(1–2): 125–134.

Chengappa, K. N., J. Levine, S. Gershon, et al. 2000. Inositol as an addon treatment for bipolar depression. Bipolar Disorders 2(1): 47–55.

Fux, M., J. Levine, A. Aviv, et al. 1996. Inositol treatment of obsessive-compulsive disorder. American Journal of Psychiatry 153(9): 1219–1221.

Кава-кава

Attele, A. S., J. T. Xie, C. S. Yuan. 2000. Treatment of insomnia: an alternative approach. Alternative Medicine Review 5(3): 249–259.

Basch, E., C. Ulbricht, P. Hammerness, et al. 2002. Kava monograph. Journal of Herbal Pharmacotherapy 2(4): 65–91.

Boerner, R. J., and S. Klement. 2004. Attenuation of neuroleptic- induced extrapyramidal side effects by Kava special extract WS 1490. Wiener Medizin i — sche Wochenschrift 154(21–22): 508–510.

Pittler, M. H., and E. Ernst. 2003. Kava extract for treating anxiety. Cochrane Database of Systatic Reviews Issue 1. Art. No.: CD003383. DOI: 10. 1002/14651858. CD003383.

Scherer, J. 1998. Kava-kava extract in anxiety disorders: an outpatient observational study. Advances in Therapy 15(4): 261–269.

Кетогенная диета для эпилепсии и других психиатрических расстройств.

Farasat, S., Е. Н. Kossoff, D. J. Pillas, et al. 2006. The importance of parental expectations of cognitive improvement for their children with epilepsy prior to starting the ketogenic diet. Epilepsy & Behavior 2006 8(2): 406–410.

Kossoff, Е. Н., L. С. Laux, R. Blackford, et al. 2008. When do seizures usually improve with the ketogenic diet? Epilepsia 49(2): 329–333.

Martinez, C. G, P. L. Pyzik, and E. H. Kossoff. 2007. Discontinuing the ketogenic diet in seizure- free children: recurrence and risk factors. Epilepsia 48(1): 187–190.

Neal, E. G., H. Chaffe, R. H. Schwartz, et al. 2008. The ketogenic diet for the treatment of childhood epilepsy: A randomised controlled trial. Lancet Neurology 7(6): 500–506.

Аутизм

Evangeliou, A., I. Vlachonikolis, H. Mihailidou, et al. 2003. Application of a ketogenic diet in children with autistic behavior: pilot study. Journal of Child Neurology 18(2): 113–118.

Поведение